Factors affecting market access of biosimilars

 posted 03/02/2012

Growth in the use of biosimilars is being driven by the need to reduce healthcare costs, patent expiries on blockbuster originator biologicals and better-def...

more
Generic and biosimilar user fee recommendations... Generics/News | Posted 03/02/2012
Production of 24 biosimilars in Iran by 2012 Biosimilars/News | Posted 03/02/2012
Suppliers of products on the drug shortages lis... Reports | Posted 03/02/2012
Italy asked to comply with marketing rules for... Generics/News | Posted 03/02/2012
Actavis and Bioton form joint venture for insulin Pharma News | Posted 03/02/2012
Amphastar and Watson launch biosimilar enoxaparin Biosimilars/News | Posted 03/02/2012
Generics market to experience strong growth in... Generics/Research | Posted 03/02/2012
EMA publishes draft biosimilar guideline for in... Guidelines | Posted 27/01/2012
Sandoz starts phase III trials for biosimilar f... Biosimilars/News | Posted 27/01/2012
Physician perceptions of generics substitution Biosimilars/Research | Posted 27/01/2012
Roche encounters manufacturing issues with epoe... Biosimilars/News | Posted 27/01/2012
Which drugs are affected by drug shortages in t... Reports | Posted 27/01/2012
Watson expands in Asia with Ascent Pharmahealth Generics/News | Posted 27/01/2012
Australia’s biggest-ever generics price cuts co... Policies & Legislation | Posted 27/01/2012
Drug shortage woes continue in the UK Pharma News | Posted 27/01/2012
World Generic Medicines Congress Europe 2012 Conferences | Posted 27/01/2012
World Generic Medicines Congress Americas 2012 Conferences | Posted 27/01/2012
Relative effectiveness and cost minimisation fo... Biosimilars/Research | Posted 20/01/2012
Investigating drug shortages in the US Reports | Posted 20/01/2012
Factors important for generics substitution in... Generics/Research | Posted 20/01/2012
Proposed biosimilars guidelines for Chile Guidelines | Posted 20/01/2012
Shortages of ADHD drugs expected during 2012 Pharma News | Posted 20/01/2012
Teva outlines expansion plans in Asia Generics/News | Posted 20/01/2012
Baxter and Momenta make biosimilars deal Biosimilars/News | Posted 20/01/2012
Generic nasal spray approved by FDA Generics/News | Posted 20/01/2012
10th EGA International Symposium on Biosimilar... Conferences | Posted 20/01/2012
Biosimilars Asia 2012 Conferences | Posted 20/01/2012
Comparability for Biologics 2012 Conferences | Posted 20/01/2012
Biosimilars - Prague, Czech Republic Conferences | Posted 20/01/2012
Top developments in biosimilars during 2011 Biosimilars/General | Posted 13/01/2012
Amgen finally jumps on biosimilars bandwagon Biosimilars/News | Posted 13/01/2012
Problematic pharma patent settlements decrease... Reports | Posted 13/01/2012
Hospira starts phase III programme for biosimil... Biosimilars/News | Posted 13/01/2012
India at the biotech crossroads Biosimilars/Research | Posted 13/01/2012
UK drug shortages are far from being solved Pharma News | Posted 13/01/2012
First biosimilar G-CSF in Japan Biosimilars/News | Posted 13/01/2012
Teva gains tentative approval for generic atorv... Generics/News | Posted 13/01/2012
Biosimilars and Biobetters: Technologies &... Conferences | Posted 13/01/2012
The cost-effectiveness of biosimilars Biosimilars/Research | Posted 16/12/2011
How originator companies delay generic medicines Reports | Posted 16/12/2011
Samsung makes biosimilars deal with Biogen Idec Biosimilars/News | Posted 16/12/2011
FDA biosimilar user fees meeting Biosimilars/General | Posted 16/12/2011
UK drug shortages continue to affect pharmacist... Pharma News | Posted 16/12/2011
Health Canada definitions of generics and biosi... Biosimilars/General | Posted 16/12/2011
Pfizer continues to fight for Lipitor Generics/News | Posted 16/12/2011
Ranbaxy may settle with FDA for generic atorvas... Generics/News | Posted 16/12/2011
EMA to revise overarching biosimilar guidelines Guidelines | Posted 09/12/2011
Interchangeability (switching and alternating)... Biosimilars/Research | Posted 09/12/2011
Quality by design for generics by 2013 Generics/General | Posted 09/12/2011
more

Country Focus

All countries

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048